Portfolio company
Numen
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
Numen develops rapid at-home urine tests for early cancer detection, serving individuals at risk of cancer and healthcare providers.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
LEUKO
This company develops a non-invasive device for monitoring white blood cell levels at home for cancer patients undergoing chemotherapy.
OXCan
This company develops blood tests using proteomics and machine learning to enable early cancer detection for healthcare providers and patients.
Epiliquid
This company develops blood-based liquid biopsy tests for early cancer detection and monitoring, serving clinical laboratories and medical practitioners.
SpotItEarly
The company develops an artificial intelligence and canine-based breath test for early cancer screening in individuals and high-risk groups.
MyUTI
This company provides diagnostic laboratory testing kits and telehealth services for individuals suffering from urinary tract infections and related pelvic health issues.
Convergent Genomics
This company develops non-invasive urine-based genomic tests to detect and monitor bladder cancer for clinicians and their patients.
52 North
This company develops point-of-care diagnostic devices and digital tools for cancer patients to monitor life-threatening complications like neutropenic sepsis at home.
KidneyMetrix
The company develops an artificial intelligence platform using non-invasive sampling to provide early diagnostic insights for kidney injuries to healthcare providers.